APRN: Shedding Light on Prostate Cancer
Prostate cancer is the most commonly diagnosed cancer in men in the United States, with 64% of all prostate cancers diagnosed in men over age 65. With the widespread adoption of prostate-specific antigen (PSA) screening, 58% of men over age 50 were screened for prostate cancer in 2003, an increase of 17% from 2000. The CDC reports that the number of deaths from prostate cancer in 2006 was 28,372 or 19.2 per 100,000 males. A high proportion of prostate cancer diagnoses are now made when tumors are nonpalpable and localized to the prostate gland. Many of these early-stage cancers are indolent or slow growing, do not progress, are not a threat to mortality, and do not lead to early death. As the aging population grows, so will the number of prostate cancer cases. Risk factors for the disease may be found in family history, a high-fat American diet, smoking, and other known cancer risks. APRN can help with the diagnosis and treatment support of patients with prostate cancer.
Purpose/Goal: To provide the APRN with updated information on the incidence, diagnosis, and management of prostate cancer.
1. Recognize the incidence and risk for prostate cancer.
2. Identify signs, symptoms, and diagnosis for prostate cancer.
3. State indications for, and related adverse reactions of, prostate cancer treatment.
Meredith Wallace, APRN, PhD; Donald E. Bailey, RN, PhD; John Brion, RN, PhD, CHES
The planners and author(s) of this continuing nursing education activity have disclosed no relevant financial relationships with any commercial companies pertaining to this activity.
Contact Hours: 2.5
Expiration Date: 12/31/2014
Member Price: $40.00
Non-Member Price: $60.00